Clinical Trials in Arizona

Showing 9601-9620 of 16,770 trials

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

NCT00708292

This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose. The Phase II part will investigate the efficacy of AUY922 in patients with multiple myeloma. Additionally, the study includes a Phase Ib combination part of AUY922 administered in combination with bortezomib, to determine the maximum tolerated dose of the combination drugs in patients with multiple myeloma.

Relapsed or Refractory Multiple Myeloma

Novartis Pharmaceuticals29 participantsStarted Jul 2008

Scottsdale, Arizona, United States • San Antonio, Texas, United States • Melbourne, Australia +6 more locations

COMPLETEDPhase 338 miles

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817

The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.

Post Surgical Ocular Inflammation and Pain

Kala Pharmaceuticals, Inc.520 participantsStarted Jun 2016

Chandler, Arizona, United States • Phoenix, Arizona, United States • Artesia, California, United States +32 more locations

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Find Trials by Condition in Arizona

PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Evaluation of Biomarkers of Traumatic Brain Injury

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

The CDR Implementation Trial

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)